IL-34 and M-CSF form a novel heteromeric cytokine and regulate the M-CSF receptor activation and localization.

[1]  F. Caprioli,et al.  Interleukin-34 sustains inflammatory pathways in the gut. , 2015, Clinical science.

[2]  B. Le Goff,et al.  Syndecan-1 regulates the biological activities of interleukin-34. , 2015, Biochimica et biophysica acta.

[3]  P. Roingeard,et al.  IL‐34 and macrophage colony‐stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells , 2014, Hepatology.

[4]  E. Masteller,et al.  Targeting IL-34 in chronic inflammation. , 2014, Drug discovery today.

[5]  E. Stanley,et al.  CSF-1 receptor signaling in myeloid cells. , 2014, Cold Spring Harbor perspectives in biology.

[6]  F. Yamane,et al.  CSF‐1 receptor‐mediated differentiation of a new type of monocytic cell with B cell‐stimulating activity: its selective dependence on IL‐34 , 2014, Journal of leukocyte biology.

[7]  Dima Kozakov,et al.  How good is automated protein docking? , 2013, Proteins.

[8]  Erik Willems,et al.  The need for transparency and good practices in the qPCR literature , 2013, Nature Methods.

[9]  J. Marchand,et al.  Therapeutic Effects of Anti-CD115 Monoclonal Antibody in Mouse Cancer Models through Dual Inhibition of Tumor-Associated Macrophages and Osteoclasts , 2013, PloS one.

[10]  R. Head,et al.  Transcriptional profiling and pathway analysis of CSF-1 and IL-34 effects on human monocyte differentiation. , 2013, Cytokine.

[11]  M. Mehler,et al.  Receptor-type Protein-tyrosine Phosphatase ζ Is a Functional Receptor for Interleukin-34* , 2013, The Journal of Biological Chemistry.

[12]  Tania Nolan,et al.  The digital MIQE guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments. , 2013, Clinical chemistry.

[13]  S. Savvides,et al.  Human IL-34 and CSF-1 establish structurally similar extracellular assemblies with their common hematopoietic receptor. , 2013, Structure.

[14]  N. Ifrah,et al.  IL-34 Induces the Differentiation of Human Monocytes into Immunosuppressive Macrophages. Antagonistic Effects of GM-CSF and IFNγ , 2013, PloS one.

[15]  S. Savvides,et al.  Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases , 2012, Nature Reviews Cancer.

[16]  Adrian Whitty,et al.  Understanding cytokine and growth factor receptor activation mechanisms , 2012, Critical reviews in biochemistry and molecular biology.

[17]  M. Mehler,et al.  The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. , 2012, Developmental biology.

[18]  L. Williams,et al.  The mechanism of shared but distinct CSF-1R signaling by the non-homologous cytokines IL-34 and CSF-1. , 2012, Biochimica et biophysica acta.

[19]  M. Diamond,et al.  IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia , 2012, Nature Immunology.

[20]  B. Brooks,et al.  Extracellular complexes of the hematopoietic human and mouse CSF-1 receptor are driven by common assembly principles. , 2011, Structure.

[21]  M. Chemel,et al.  Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients , 2011 .

[22]  S. Okada,et al.  IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation , 2010, Cell Death and Differentiation.

[23]  L. Williams,et al.  Functional overlap but differential expression of CSF‐1 and IL‐34 in their CSF‐1 receptor‐mediated regulation of myeloid cells , 2010, Journal of leukocyte biology.

[24]  D. Heymann,et al.  Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in rankl-induced osteoclastogenesis , 2010 .

[25]  D. Hume,et al.  Pivotal Advance: Avian colony‐stimulating factor 1 (CSF‐1), interleukin‐34 (IL‐34), and CSF‐1 receptor genes and gene products , 2010, Journal of leukocyte biology.

[26]  Y. Takebe,et al.  Dys‐regulated activation of a Src tyroine kinase Hck at the Golgi disturbs N‐glycosylation of a cytokine receptor Fms , 2009, Journal of Cellular Physiology.

[27]  P. Focia,et al.  Structure of macrophage colony stimulating factor bound to FMS: Diverse signaling assemblies of class III receptor tyrosine kinases , 2008, Proceedings of the National Academy of Sciences.

[28]  L. Williams,et al.  Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome , 2008, Science.

[29]  B. Tsvetanova,et al.  Biosynthesis of the Tunicamycins: A Review , 2007, The Journal of Antibiotics.

[30]  Zhiping Weng,et al.  ZRANK: Reranking protein docking predictions with an optimized energy function , 2007, Proteins.

[31]  U. Landegren,et al.  Direct observation of individual endogenous protein complexes in situ by proximity ligation , 2006, Nature Methods.

[32]  J. Derry,et al.  Cutting Edge: Interleukin 17 Signals through a Heteromeric Receptor Complex , 2006, The Journal of Immunology.

[33]  Stephen R. Comeau,et al.  PIPER: An FFT‐based protein docking program with pairwise potentials , 2006, Proteins.

[34]  A. Reynolds,et al.  Rational siRNA design for RNA interference , 2004, Nature Biotechnology.

[35]  Li Li,et al.  RDOCK: Refinement of rigid‐body protein docking predictions , 2003, Proteins.

[36]  C. Ritzenthaler,et al.  Brefeldin A: Deciphering an Enigmatic Inhibitor of Secretion , 2002, Plant Physiology.

[37]  R. T. Sjin,et al.  Transcriptional regulation of myeloid differentiation primary response (MyD) genes during myeloid differentiation is mediated by nuclear factor Y. , 2002, Blood.

[38]  Zhiping Weng,et al.  Docking unbound proteins using shape complementarity, desolvation, and electrostatics , 2002, Proteins.

[39]  A J Olson,et al.  Structural symmetry and protein function. , 2000, Annual review of biophysics and biomolecular structure.

[40]  R. Cacan,et al.  Trafficking of oligomannosides released during N-glycosylation: a clearing mechanism of the rough endoplasmic reticulum. , 1999, Biochimica et biophysica acta.

[41]  J. Pandit,et al.  Three-dimensional structure of dimeric human recombinant macrophage colony-stimulating factor. , 1992, Science.

[42]  F. Momany,et al.  Validation of the general purpose QUANTA ®3.2/CHARMm® force field , 1992 .

[43]  E. Stanley,et al.  The predominant form of secreted colony stimulating factor-1 is a proteoglycan. , 1992, The Journal of biological chemistry.

[44]  W. Wiktor-Jedrzejczak,et al.  Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Nishikawa,et al.  The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene , 1990, Nature.

[46]  J. Vandesompele,et al.  Selection of reliable reference genes for RT-qPCR analysis. , 2014, Methods in molecular biology.

[47]  K. Ui-Tei,et al.  Designing functional siRNA with reduced off-target effects. , 2013, Methods in molecular biology.

[48]  H. Harada,et al.  Interaction between Hck and HIV-1 Nef negatively regulates cell surface expression of M-CSF receptor. , 2008, Blood.

[49]  L Adorini,et al.  The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. , 1998, Annual review of immunology.

[50]  E. Kawasaki,et al.  Molecular biology of macrophage colony-stimulating factor. , 1990, Immunology series.

[51]  Kawasaki Es,et al.  Molecular biology of macrophage colony-stimulating factor. , 1990 .